Clinical Trials Browser

lenvatinib × NET × 90 days × Clear all

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2 Recruiting

Neuroendocrine Tumors

NCT04848337 2026-02-12

PLANE-PC

Phase 2 Active not recruiting

45 enrolled 8 charts

Neuroendocrine Tumors